3/24
05:57 pm
tnya
William Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product Pipeline [Yahoo! Finance]
Medium
Report
William Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product Pipeline [Yahoo! Finance]
3/20
08:22 am
tnya
Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus [Yahoo! Finance]
Medium
Report
Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus [Yahoo! Finance]
3/14
01:32 am
tnya
Low
Report
3/12
12:06 pm
tnya
Tenaya Therapeutics (TNYA) had its "outperform" rating reaffirmed by Leerink Partners.
Low
Report
Tenaya Therapeutics (TNYA) had its "outperform" rating reaffirmed by Leerink Partners.
3/12
11:07 am
tnya
Tenaya Therapeutics (TNYA) had its "outperform" rating reaffirmed by William Blair.
Low
Report
Tenaya Therapeutics (TNYA) had its "outperform" rating reaffirmed by William Blair.
3/12
08:44 am
tnya
Tenaya Therapeutics (TNYA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $8.00 price target on the stock.
Medium
Report
Tenaya Therapeutics (TNYA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $8.00 price target on the stock.
3/11
04:38 pm
tnya
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
3/11
04:05 pm
tnya
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Medium
Report
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
3/9
08:51 am
tnya
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy [Yahoo! Finance]
Low
Report
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy [Yahoo! Finance]
3/9
08:30 am
tnya
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
Low
Report
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
3/7
05:30 am
tnya
Tenaya Therapeutics (TNYA) was upgraded by Lifesci Capital to "strong-buy".
Medium
Report
Tenaya Therapeutics (TNYA) was upgraded by Lifesci Capital to "strong-buy".
3/5
09:01 am
tnya
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics [Yahoo! Finance]
High
Report
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics [Yahoo! Finance]
3/5
08:30 am
tnya
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
High
Report
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
3/2
04:05 pm
tnya
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
Medium
Report
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
1/23
09:39 pm
tnya
Assessing Tenaya Therapeutics (TNYA) Valuation After Its US$60 Million Capital Raise And Extended Cash Runway [Yahoo! Finance]
Medium
Report
Assessing Tenaya Therapeutics (TNYA) Valuation After Its US$60 Million Capital Raise And Extended Cash Runway [Yahoo! Finance]
1/19
08:26 am
tnya
Morgan Stanley Backs Tenaya Therapeutics (TNYA) as SMID-Cap Biotech Primed to Outperform in 2026 [Yahoo! Finance]
Medium
Report
Morgan Stanley Backs Tenaya Therapeutics (TNYA) as SMID-Cap Biotech Primed to Outperform in 2026 [Yahoo! Finance]
1/9
08:30 am
tnya
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones
Low
Report
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones
1/8
10:05 am
tnya
Tenaya Therapeutics (NASDAQ:TNYA) was given a new $2.00 price target on by analysts at Morgan Stanley.
Low
Report
Tenaya Therapeutics (NASDAQ:TNYA) was given a new $2.00 price target on by analysts at Morgan Stanley.